Hi Mr Jay, can't give you links, but when i read up on the net there is a lot of trials dropping like flies and failing. Or not great results as predicted. Tyk2 etc. is similar to these products and is still going strong. Results seem good or better than our competitors. If they ( the big Pharma's) started their research again they would be lagging behind in the race. Plus they could use our compounds to mix with theirs to improve their results. The cheapest way and quickest way forward for them would be to buy us out IMHO. and have sole benefit, and employ Tim and his team as consultants......in an ideal world.
I may be miles off but that's my opinion only, right or wrong...........however, i'm still p155ed off at the timing of their nice little wage rise.
I don't think it will be 5 years. Just annoying Mr Jay as he misunderstood the milestones. Tyk2 is hot hot hot. Other companies with assets are genentech. Takeda. Biogen. Ourselves and nimbus are the only ones available to licence. I think it's only 6 months until a buyout. Possibly by nimbus. Now the directors are optioned up hopefully they will stop depressing the share price whenever it rises. Or they risk being bought out on the cheap. Parker was brought on board for a reason. And his pay rise and options suggest he has already earned it. We will find out in due course.
I agree that it seems strange they are getting this almost straight away without a vesting period and without the share price or value of the company changing that much even though they have managed a licence agreement, i would hope that there is something that they know about that we don't that will justify this very generous payment. I also agree with Minden, i have held for longer than his 6 i think and i would be gutted if this takes another 5 to realise any serious potential. GLA
you didn't listen to the interview properly. I suggest you re listen and read some research on how milestones are structured. The small size of the upfront suggests it is bac end loaded which could be 5 years away
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.